Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock suffered a major decline of -11.2% on 5/9/24. The shares closed at $15.21. Moreover, exceptionally high trading volume at 286% of normal accompanied the decline. Relative to the market the stock has been extremely weak over the last nine months and has declined -10.8% during the last week.
Current PriceTarget Research Rating
ACAD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Acadia Pharmaceuticals has a poor Appreciation Score of 20 and a very low Power Rating of 10, leading to the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment